Actithera is a technology company.
Actithera is a technology company.
Actithera has raised $76.0M across 1 funding round.
Actithera has raised $76.0M in total across 1 funding round.
Actithera has raised $76.0M in total across 1 funding round.
Actithera's investors include Cambridge Innovation Capital, MP Healthcare Venture Management, Hakan Goker, Noga Yerushalmi, Therese Liechtenstein, M Ventures (Merck), SV Health Investors.
Actithera is a biotechnology company developing next-generation radioligand therapies (RLTs) for cancer treatment, translating medicinal chemistry into radiopharmaceuticals that achieve prolonged tumor retention and rapid systemic clearance.[1][3] It serves cancer patients with high unmet needs in oncology by addressing limitations of current therapies through a proprietary three-pillar discovery platform featuring covalent targeting strategies, rational drug design, and an isotope-agnostic approach for alpha or beta emitters.[1][4] Founded in 2021 and backed by a $75.5M oversubscribed Series A in July 2025 co-led by M Ventures, Hadean Ventures, Sofinnova Partners, and 4BIO Capital, Actithera shows strong growth momentum with an advancing preclinical pipeline, including a lead FAP-targeting candidate, and recent licensing of innovative covalent chemistries from the Weizmann Institute.[1][5]
Actithera was founded in 2021 by Dr. Andreas Goutopoulos, a drug discovery expert with deep expertise in small molecule oral drug design, who sought to apply structure-based and kinetics-driven principles to radiopharmaceuticals.[1][3] The idea emerged from recognizing gaps in existing RLTs, such as insufficient tumor residence time, leading to the creation of a platform combining medicinal chemistry and radiochemistry for superior radioligands.[1][2] Early traction came via seed investment from M Ventures and Arkin Bio Ventures (noted as incepted in 2020 in some records), enabling headquarters in Oslo, Norway, and Cambridge, Massachusetts, and rapid progress to a differentiated pipeline targeting solid tumors.[1][2][3]
Actithera stands out in radiopharmaceuticals through these key strengths:
Actithera rides the explosive growth in radiopharmaceuticals, fueled by successes like Pluvicto and Zevalin, which validate RLTs for precision oncology amid rising demand for targeted therapies over imprecise chemotherapies or external beam radiation.[4] Timing is ideal post-2025 Series A funding and Weizmann licensing, aligning with market forces like expanding radioisotope supply chains and regulatory momentum for alpha/beta emitters in metastatic cancers.[1][5] By pioneering covalent retention for longer-lived isotopes, Actithera influences the ecosystem toward more efficacious, patient-friendly dosing—potentially fewer cycles and better quality of life—while its global investor syndicate (e.g., Sofinnova, 4BIO) accelerates biotech innovation in difficult-to-treat solid tumors.[1][3]
Actithera's near-term path centers on advancing its FAP-targeting lead to clinical trials, leveraging $75.5M funding to expand the pipeline across oncology indications with Weizmann-enhanced chemistries.[1][5] Trends like alpha-emitter scalability and AI-driven drug design will shape its trajectory, enabling broader adoption amid a projected $20B+ radiopharma market by 2030. Its influence may evolve from preclinical innovator to category leader, delivering transformative RLTs that redefine cancer care with superior efficacy and safety—validating Goutopoulos's vision from day one.[1][3]
Actithera has raised $76.0M across 1 funding round. Most recently, it raised $76.0M Series A in July 2025.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2025 | $76.0M Series A | Cambridge Innovation Capital, MP Healthcare Venture Management, Hakan Goker, Noga Yerushalmi, Therese Liechtenstein, M Ventures (Merck), SV Health Investors |